Anthem Biosciences Limited (NSE:ANTHEM)
India · Delayed Price · Currency is INR 809.85
+10.80 (1.35%)
May 13, 2026, 3:30 PM IST
Anthem Biosciences Revenue
Anthem Biosciences had revenue of 4.23B INR in the quarter ending December 31, 2025, a decrease of -15.00%. This brings the company's revenue in the last twelve months to 20.02B, up 12.68% year-over-year. In the fiscal year ending March 31, 2025, Anthem Biosciences had annual revenue of 18.50B with 30.29% growth.
Revenue (ttm)
20.02B
Revenue Growth
+12.68%
P/S Ratio
22.41
Revenue / Employee
10.20M
Employees
1,825
Market Cap
448.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.50B | 4.30B | 30.29% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | 11.05B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 168.27B |
| Dishman Carbogen Amcis | 27.97B |
| OneSource Specialty Pharma | 14.19B |
| Concord Biotech | 11.59B |
| Blue Jet Healthcare | 10.53B |
| Supriya Lifescience | 7.35B |
| Panacea Biotec | 6.06B |
| Zota Health Care | 4.73B |
Anthem Biosciences News
- 3 months ago - Anthem Biosciences Transcript: Q3 25/26 - Transcripts
- 6 months ago - Anthem Biosciences Transcript: Q2 25/26 - Transcripts
- 9 months ago - Anthem Biosciences Transcript: Q1 25/26 - Transcripts